Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Total Liabilities: 2009-2024

Historic Total Liabilities for Northwest Biotherapeutics (NWBO) over the last 16 years, with Dec 2024 value amounting to $105.7 million.

  • Northwest Biotherapeutics' Total Liabilities rose 34.52% to $125.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $125.9 million, marking a year-over-year increase of 34.52%. This contributed to the annual value of $105.7 million for FY2024, which is 41.09% up from last year.
  • Latest data reveals that Northwest Biotherapeutics reported Total Liabilities of $105.7 million as of FY2024, which was up 41.09% from $74.9 million recorded in FY2023.
  • Over the past 5 years, Northwest Biotherapeutics' Total Liabilities peaked at $395.8 million during FY2020, and registered a low of $74.9 million during FY2023.
  • In the last 3 years, Northwest Biotherapeutics' Total Liabilities had a median value of $105.7 million in 2024 and averaged $105.7 million.
  • As far as peak fluctuations go, Northwest Biotherapeutics' Total Liabilities skyrocketed by 610.70% in 2020, and later crashed by 58.53% in 2021.
  • Northwest Biotherapeutics' Total Liabilities (Yearly) stood at $395.8 million in 2020, then tumbled by 58.53% to $164.2 million in 2021, then declined by 16.93% to $136.4 million in 2022, then plummeted by 45.06% to $74.9 million in 2023, then surged by 41.09% to $105.7 million in 2024.